The clinical team of pharmacokinetic (PK)/ pharmacodynamic (PD) data analysts and consultants at Venn Life Sciences performed the non-compartmental analysis (NCA) required for regulatory submission in an oncology trial involving a uniquely designed antibody as part of a combination therapy.
